Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: application for a pharmacokinetic study.

[1]  Thomas Jaki,et al.  Estimation of pharmacokinetic parameters with the R package PK , 2011 .

[2]  G. Zapata-Sudo,et al.  LASSBio-294, A compound with inotropic and lusitropic activity, decreases cardiac remodeling and improves Ca²(+) influx into sarcoplasmic reticulum after myocardial infarction. , 2010, American journal of hypertension.

[3]  Fei Cai,et al.  Simultaneous determination of five lignan constituents of Wuzhi capsule in rat plasma by LC-MS/MS: application to pharmacokinetic study. , 2010, Journal of pharmaceutical and biomedical analysis.

[4]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[5]  Carolina H Andrade,et al.  Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. , 2010, Bioorganic & medicinal chemistry letters.

[6]  Hongda Ma,et al.  Simultaneous determination of tetrahydropalmatine, protopine, and palmatine in rat plasma by LC-ESI-MS and its application to a pharmacokinetic study. , 2009, Journal of pharmaceutical and biomedical analysis.

[7]  Ragu Ramanathan,et al.  Mass spectrometry in drug metabolism and pharmacokinetics , 2008 .

[8]  S. Jackson,et al.  Antiplatelet therapy: in search of the 'magic bullet' , 2003, Nature Reviews Drug Discovery.

[9]  Eliezer J. Barreiro.  Estratégia de simplificação molecular no planejamento racional de fármacos: a descoberta de novo agente cardioativo , 2002 .

[10]  E. Barreiro,et al.  Cyclic GMP‐dependent vasodilatory properties of LASSBio 294 in rat aorta , 2002, British journal of pharmacology.

[11]  E. Albuquerque,et al.  A novel thienylhydrazone, (2-thienylidene)3,4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle. , 2001, The Journal of pharmacology and experimental therapeutics.

[12]  E. Barreiro,et al.  The new compound, LASSBio 294, increases the contractility of intact and saponin‐skinned cardiac muscle from Wistar rats , 2001, British journal of pharmacology.

[13]  L. M. Lima,et al.  Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole. , 2000, European journal of medicinal chemistry.

[14]  E. Barreiro,et al.  CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. , 2011, European journal of medicinal chemistry.

[15]  E. Barreiro,et al.  Medicinal chemistry of N-acylhydrazones: new lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. , 2006, Current medicinal chemistry.

[16]  Juliette Martin,et al.  Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. , 2006, Frontiers in bioscience : a journal and virtual library.

[17]  I. Nnane,et al.  DRUG METABOLISM | Metabolite Isolation and Identification , 2005 .

[18]  Colin F. Poole,et al.  Encyclopedia of analytical science , 1995 .